September 26, 2023

Catalyzing Change: Young Moroccan Oncologists Spearhead the Fight Against Sarcoma

Discover the latest insights into sarcoma and rare adult solid cancers from the recent ESMO Sarcoma and Rare Cancers Congress, underlining the significance of multidisciplinary approaches and research efforts. Voices from young oncologists shed light on the pressing need for qualified resources. #ESMO2023

The ASCO Post

January 25, 2023

Communicating Prognosis: A Core Competency of Patient-Centered Oncology Care

Physicians tackle challenges discussing prognosis due to inadequate formal training and the discomfort of the conversations. Redefining prognosis can alleviate patients' fears about the future. Click to learn evidence-based tools for better communication.

The ASCO Post

July 11, 2024

Association of Genetic Risk for Prostate Cancer With Early Prostate Cancer Death

A recent cohort study found that men at a higher genetic risk for prostate cancer were more likely to experience early death from prostate cancer compared to men with a lower genetic risk for the dise...

The ASCO Post

January 25, 2023

Expert Point of View: Bita Fakhri, MD, MPH

Renowned Assistant Professor of Medicine at Stanford Medicine, Dr. Bita Fakhri, sheds light on the ongoing phase III CLL13 trial and the potential impact of adding an anti-CD20 monoclonal antibody to venetoclax and ibrutinib. She emphasizes the critical need for longer follow-up data to assess its effectiveness.

The ASCO Post

October 25, 2023

ASCO Response to Drug Shortages Request for Information

The Association for Clinical Oncology (ASCO) responded to a bicameral Request for Information (RFI) on the underlying factors driving drug shortages. The Association’s comments highlighted the impact ...

The ASCO Post

August 17, 2023

Ruxolitinib Demonstrates Clinical Activity in a Phase II Trial of Chronic Myelomonocytic Leukemia

In a phase II trial, treatment with the JAK2 inhibitor ruxolitinib resulted in clinical activity in two-thirds of patients with chronic myelomonocytic leukemia with splenomegaly or an otherwise high d...

The ASCO Post

September 25, 2024

Cancer Rates Recover, Rebound Eludes 2021 Data

Cancer rates returned to near prepandemic levels in 2021, however, distant-stage breast cancer incidence surpassed expectations, signaling potential COVID-19 screening disruption effects.

Conexiant

August 09, 2023

Erdafitinib for Patients With FGFR-Altered Advanced Solid Tumors

In the phase II RAGNAR study reported in The Lancet Oncology, Shubham Pant, MBBS, and colleagues found that the pan-FGFR tyrosine kinase inhibitor erdafitinib showed activity in patients with advanced...

The ASCO Post

February 10, 2023

FDA Oncology Center of Excellence Seeks Applications for New Research Funding Opportunities

Staff from the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA) discuss extramural research funded by the OCE, focusing on research that addresses questions identifie...

The ASCO Post